Safety and Tolerability of Cilofexor in Participants With Primary Sclerosing Cholangitis (PSC) and Compensated Cirrhosis

Phase 1

Terminated

Brief Summary: The primary objective of this study is to assess the safety and tolerability of escalating doses of cilofexor (CILO) in participants with primary sclerosing cholangitis (PSC) and compensated cirrhosis.

Recruitment & Eligibility

Inclusion Criteria

Diagnosis PSC based on cholangiogram (magnetic resonance cholangiopancreatography [MRCP], endoscopic retrograde cholangiopancreatography [ERCP], or percutaneous transhepatic cholangiogram [PTC]) or liver biopsy
Individuals have evidence of cirrhosis based on historical liver biopsy, abdominal imaging [magnetic resonance imaging (MRI), computed tomography (CT), or Ultrasound], or a screening FibroScan®, enhanced liver fibrosis (ELF)™, or FibroTest®.
Individual has the following laboratory parameters at the Screening visit, as determined by the central laboratory:
- Estimated glomerular filtration rate (eGFR) > 60 milliliter/minute (mL/min), as calculated by the Cockcroft-Gault equation
- Alanine aminotransferase (ALT) ≤ 5 x upper limit of the normal (ULN)
- Total 2 milligram/deciliter (mg/dL), unless the individual is known to have Gilbert's syndrome or hemolytic anemia
- International normalized ratio (INR) ≤ 1.4, unless due to therapeutic anticoagulation
- Platelet count ≥ 75,000/microliter (μL). Individuals with evidence of high-risk esophageal or gastric varices in the opinion of the investigator are excluded
- Negative anti-mitochondrial antibody

Key

Exclusion Criteria

Current or prior history of any of the following
- Decompensated liver disease, including ascites, hepatic encephalopathy (HE), or variceal hemorrhage
- Liver transplantation
- Cholangiocarcinoma or hepatocellular carcinoma (HCC).
Model for End-stage Liver Disease (MELD) score > 12 at Screening, unless due to an alternate etiology such as therapeutic anticoagulation
Child-Pugh (CP) score > 6 at Screening, unless due to an alternative etiology such as Gilbert's syndrome or therapeutic anticoagulation
Current moderate to severely active inflammatory bowel disease (IBD) (including ulcerative colitis, Crohn's disease, and indeterminate colitis).
- Note: Individuals with IBD who currently have an external ostomy bag and/or proctocolectomy are not subject to this exclusion criterion and need not undergo IBD Symptom Severity Assessment.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Arm && Interventions

Group	Intervention	Description
Cilofexor	Cilofexor	Participants will receive escalating doses of cilofexor 30 mg, 60 mg, and 100 mg.

Primary Outcome Measures

Name	Time	Method
Percentage of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs)	First dose date up to 12 weeks plus 30 days	Treatment-emergent adverse events (TEAEs) were either defined any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug or any AEs leading to premature discontinuation of study drug.
Percentage of Participants Who Experienced Laboratory Abnormalities	First dose date up to 12 weeks plus 30 days	Treatment-emergent laboratory abnormalities are defined as values that increase at least 1 toxicity grade from baseline at any postbaseline time point, up to and including the date of last dose of study drug plus 30 days. Grade 1: mild; Grade 2: moderate; Grade 3: severe; Grade 4: life-threatening.
Percentage of Participants Who Experienced Treatment Emergent Serious Adverse Events (SAEs)	First dose date up to 12 weeks plus 30 days	A treatment emergent SAE was defined as an event that, at any dose, resulted in the following: death ; life-threatening situation; in-patient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; a congenital anomaly/birth defect; a medically important event or reaction: such events may not be immediately life-threatening or result in death or hospitalization but may jeopardize the subject or may require intervention to prevent one of the other outcomes constituting SAEs.

Secondary Outcome Measures

Name	Time	Method

Locations (16): Arizona Liver Health
🇺🇸
Chandler, Arizona, United States
California Liver Research Institute
🇺🇸
Pasadena, California, United States
University of California San Francisco, Liver Clinic
🇺🇸
San Francisco, California, United States
Piedmont Atlanta Hospital
🇺🇸
Atlanta, Georgia, United States
Schiff Center for Liver Diseases/University of Miami
🇺🇸
Miami, Florida, United States
Indiana University Health University Hospital
🇺🇸
Indianapolis, Indiana, United States
Minnesota Gastroenterology, PA
🇺🇸
Maplewood, Minnesota, United States
Louisiana Research Center, LLC
🇺🇸
Shreveport, Louisiana, United States
Northwell Health Center for Liver Diseases and Transplantation
🇺🇸
Manhasset, New York, United States
The Liver Institute at Methodist Dallas Medical Center
🇺🇸
Dallas, Texas, United States
University of Virginia Medical Center
🇺🇸
Charlottesville, Virginia, United States
University of Rochester Medical Center
🇺🇸
Rochester, New York, United States
VCU Clinical Research Services Unit (CRSU) [Patient Site Address]
🇺🇸
Richmond, Virginia, United States
University of Washington at Harborview Medical Center
🇺🇸
Seattle, Washington, United States
Bon Secours Richmond Community Hospital, Inc. d/b/a Bon Secours Liver Institute of Richmond
🇺🇸
Richmond, Virginia, United States
Liver Institute Northwest
🇺🇸
Seattle, Washington, United States